Capsules & Health Ingredients

Market Trends

The Capsules & Health Ingredients division serves two primary markets – Pharmaceutical and Nutraceutical. Within the capsules industry we are seeing different dynamics by market:

  • Within the Nutraceutical market, the industry benefited from surge demand caused by COVID-19, beyond normal growth rates, as consumers increased their consumption of nutritional and dietary supplements. Apart from COVID-19, we saw more nutraceutical companies introducing new products to the market and using specialty capsules and dosage forms solutions to differentiate themselves. We continue to see end consumer preference trending toward clean label and vegetarian-based capsules. Healthier living and demographic shift to older population remain the key driver for Nutraceutical capsules and ingredients growth, further accelerated by COVID-19.
  • In the Pharmaceutical market, COVID-19 impacted supply and demand for pharmaceutical capsules, lowering projected industry growth rates. We saw a decline for some medications, as some patients deferred elective medical procedures as a result of COVID-19. This was partially offset with increased demand for selected over-the-counter (OTC) medication. As we enter 2021, we expect the pharmaceutical market to remain relatively flat. However, we do see longer-term opportunities as we track the drug development pipeline for more complex drugs requiring specialized capsules to overcome bioavailability challenges or requiring multi-excipient drugs, such as those used in oncology. In addition, in many regions, end-patient preference is trending to capsule oral dosage forms.

From a geographic perspective, there was a strong demand for Nutraceuticals coming from North America and steady demand for Pharmaceuticals in EMEA. We see continued increasing demand for both segments in Asia-Pacific markets, especially in generic drugs and the traditional medicine products in China and India.

Our Offerings

Our Capsules & Health Ingredients division is the trusted partner in innovative capsules, dosage form solutions and health ingredients for pharmaceutical and nutraceutical companies.

Our capsules business portfolio has two sub-businesses: empty hard capsules, and liquid-filled hard capsules. In addition, our Dosage Form Solutions portfolio offers formulation and manufacturing services to allow our customers to customize their liquid-filled hard capsules. Alternatively, for customers looking to go to market quickly, we offer “ready-to-go” ingredients, as well as pre-filled liquid or semi-solid hard capsules.

 

Billion Capsules Produced Annually in 2020

> 

Customers Worldwide

 

Production Sites

Customers benefit from our rich and extensive end-consumer market insights and long-standing expertise in dose delivery science. This has enabled us to develop a comprehensive range of proprietary dosage forms and delivery technologies. These include targeted delivery, liquid-filled hard capsules, capsule-in-a-capsule or tablet-in-a-capsule solutions and lipid multi-particulates.

We also offer integrated product design, development, clinical supply and commercial manufacturing services to our customers around the world. Our diversified customer base includes companies that make branded, generic and over-the-counter medicines in the pharmaceuticals market, and branded, proprietary, and generic supplements in the nutraceutical market.

In addition to our broad capsule range, we offer a selected portfolio of high-quality nutritional ingredients across joint health, active nutrition, digestive and immune health, weight management, sports activities and pet nutrition.

Our Portfolio

This has images

Our Global Development and Manufacturing Footprint

We serve more than 5,000 customers around the world thanks to a state-of-the-at network of 10 production sites across three continents.

This has images This has images This has images

Highlights and Initiatives

The Capsules & Health Ingredients business has maintained operations and business continuity throughout 2020. There was high capacity utilization across existing assets, which led to increased lead time for capsule products. We reported high single-digit sales growth for the full year, mainly driven by our nutritional offerings.

Throughout 2020, we have benefited from increased consumer interest, driven by COVID-19 pandemic. With limited disruption to the manufacturing network arising from the pandemic, we began expanding our capacity to meet increased demand for both nutrition capsules and health ingredients. In addition we made the decision to invest to increase our overall capsule capacity from 230 billion to 260 billion capsules annually by 2022. This additional manufacturing capacity will address the growth across our gelatin, vegetarian and specialty polymers portfolio, as well as the liquid-filled hard capsules sold under the Licaps® brand. The investment will be made over two fiscal years, 2020 and 2021, across eight global manufacturing sites.

Looking ahead to 2021 and beyond, our business priority is to accelerate our profitable growth by meeting our customers’ evolving needs to deliver more complex drugs, cleaner vegetable-based dosage forms and ingredients that enable healthier living. We will continue to develop new innovative capsules, enhance drug delivery and improve our operational and functional efficiencies.

Personal Perspectives

Claude Dartiguelongue

Capsules & Health Ingredients

As a newly-formed division the Capsules & Health Ingredients (CHI) business has delivered a strong financial performance against the backdrop of a world pandemic.

Discover More

Pharma Capsules

In 2020, we introduced an enhanced product line, aimed at tackling concerns around bias during blind clinical trials. Capsugel® DBcaps® double-blinded capsules are designed to provide an over-encapsulation of the drug to overcome the challenges of blinding products during clinical trials. The portfolio now covers a broad range, including both gelatin and FSC-certified hypromellose (HPMC) variations, making it suitable for use with multiple formulation properties and multiple oral dosage form sizes. In late 2020, Capsugel® DBcaps® capsules received the CPhI Pharma 2020 Award for Excellence in Pharma: Finished Formulation. This was assessed against a very demanding set of criteria, including product innovation, purpose, problem-solving capacity and competitive advantage.

Nutritional Capsules

Throughout 2020, we have continued to bring new consumer-driven capsule innovations to the market. For instance, we extended the range of our clean-label colored capsules. The different color options are achieved using a variety of plant-based foods, with Vcaps® Plus Spicy Yellow and Red Radish capsules now launched into the North American market.

Further, our customers continue to leverage our dosage form solutions. We assisted a wide range of product introductions, from mood, immunity, and digestive health to personal care supplements for skin and hair. Technology and dosage forms continue to solve a variety of problems, including the following:

  • DUOCAP®, DuoTablet, Minitabs, Beadlets, and Snow Globes: to solve various delivery problems including stability, release profiles, and compatibility
  • Liquid fills (LiCaps®): to help stabilize challenging formulas with our unique polymer selections such as PlantCaps® for oxidation protection or DRCaps® for acid protection products
  • Lipid Multi-Particulate technologies: to improve ingredient delivery.

Nutritional Ingredients

Within health ingredients, we announced the launch of a new and unique probiotic strain TWK10®, isolated from Taiwanese Kimchi. A novel probiotic designed to deliver sports nutrition benefits for both elite athletes and active consumers, the TWK10® brand has been clinically shown to enhance endurance, improve body composition and energy levels. Licensed exclusively from Synbio Tech, the clean label vegan ingredient can be used in dietary supplements and in foods, with additional applications already in development. The TWK10® probiotic is now available in North America.